Neurotoxicity (=ICANS) is common with CD19-directed CAR T cell therapy. We now show that biomarkers of glial and neuronal injury increase during ICANS in pediatric patients. Extremely high pre-CAR T levels correlated with prior chemo and radiation.
https://t.co/QrmC1Tzg1i
Our study on mechanisms of #CarT neurotoxicity is published! Critical to understand the "dark side" of a revolutionary cancer treatment. Congrats to the amazing @FaulhaberLila and corresponding author @GustJuliane! @seattlechildren
https://t.co/BJDd6f65Na
On behalf of our amazing team at @seattlechildren and @SCTherapeutics, I’m so proud to share preliminary results from the first trial delivering repeated intracranial doses of CAR T cells to children with brain and spinal cord tumors in @naturemedicine.
https://t.co/mkKQZrCMkQ
Delighted to share this collaborative #CancerNeuroscience study with @GutmannLab, led by the brilliant @YuanPan3, demonstrating that retinal neuronal activity is required for the initiation and growth of optic #gliomas in a mouse model of #NF1
https://t.co/3NYkaZaRai
#CarT#CellTherapy is a revolutionary cancer treatment, but neurotoxicity is a side effect for some patients.
Using a mouse model and #twophoton imaging, @GustJuliane and @FaulhaberLila show that plugging of brain capillaries is a potential mechanism.
https://t.co/ZpU6UGxrAo